Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent

16Citations
Citations of this article
29Readers
Mendeley users who have this article in their library.

Abstract

A novel bacteriophage CUB19 specific to the bacterial species Stenotrophomonas maltophilia was isolated from hospital sewage and characterized as a new species belonging to a proposed new phage genus ‘Cubvirus’ (Caudoviricetes). Its genome contains a total of 48,301 bp and 79 predicted genes, among which some have been associated with packaging and lysis-associated proteins, structural proteins, or DNA- and metabolism-associated proteins. No lysogeny-associated proteins or known virulence proteins were identified on the phage genome. CUB19 showed stability over a wide range of temperatures (−20 °C–60 °C) and pH values (pH 3–pH 13). Despite its narrow host range, this phage has potent observed antimicrobial and antibiofilm activity. A time-killing curve assay showed significant biofilm reduction after 24 h exposure to CUP19. Isothermal microcalorimetry assays investigating phage-antibiotic combinations revealed the effectiveness of CUB19 during co-administration with increasing antibiotic doses, regardless of the administration approach (simultaneous or staggered). These are encouraging indications for its application as a targeted therapeutic agent against resilient biofilm-associated Stenotrophomonas infections.

Cite

CITATION STYLE

APA

Fanaei Pirlar, R., Wagemans, J., Kunisch, F., Lavigne, R., Trampuz, A., & Gonzalez Moreno, M. (2022). Novel Stenotrophomonas maltophilia Bacteriophage as Potential Therapeutic Agent. Pharmaceutics, 14(10). https://doi.org/10.3390/pharmaceutics14102216

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free